Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a sterile injectable solution for subcutaneous administration. It is employed in the management of rheumatoid arthritis, severe plaque psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and medically indicated ectopic pregnancy, providing disease‑modifying and cytotoxic effects in these conditions.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and offering reliable global distribution.

Methofill (methotrexate) is used in several disease‑modifying and oncologic indications. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and reduces plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor regression as part of chemotherapy regimens. - Ectopic pregnancy: terminates trophoblastic tissue when medical management is chosen.

Methofill may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Fatigue: general tiredness. - Mouth sores: oral mucositis. - Elevated liver enzymes: transient hepatic enzyme rise.

Serious or Rare Side Effects: - Severe liver toxicity: hepatitis or fibrosis. - Pulmonary fibrosis: interstitial lung disease. - Bone marrow suppression: severe pancytopenia. - Severe infection: opportunistic infections due to immunosuppression.

When using Methofill, several safety considerations are essential. - Pregnancy: contraindicated (Category X) due to teratogenic risk. - Renal function: assess before use and monitor because the drug is renally excreted. - Liver function: monitor hepatic enzymes regularly. - Hematologic status: obtain baseline CBC; watch for cytopenias. - Concomitant NSAIDs: avoid or use with caution due to increased toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: risk of severe infection. - NSAIDs: increased methotrexate toxicity. - Proton pump inhibitors: may raise methotrexate levels. - Trimethoprim‑sulfamethoxazole: enhanced myelosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppression. - Penicillins: possible increased toxicity. - Oral contraceptives: reduced efficacy.